Treatment and Clinical Characteristics in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) using Talazoparib and Enzalutamide (tala+enza) Combination Therapy First published 01/08/2025 Last updated 23/10/2025 EU PAS number:EUPAS1000000580 Study Ongoing